
Biodesix Inc (BDSX) Stock Forecast & Price Target
Biodesix Inc (BDSX) Analyst Ratings
Bulls say
Biodesix is benefiting from a rebuilding sales force, stronger physician acquisition trends, and early signs that its Nodify lung-nodule franchise is gaining durable adoption, especially as CDT utilization rises and reimbursement improves. Its 2Q26 results reinforce the thesis: revenue grew 34.2% to $26.9M, diagnostic testing revenue rose 41.6% on 20,900 tests, gross margin expanded to 82%, and the adjusted EBITDA loss narrowed 56% to $3.2M, suggesting operating leverage is improving. The long-term outlook is further supported by a differentiated MRD strategy spanning both tumor-informed and tumor-naïve approaches, plus scalable health-system implementations that could deepen account penetration and broaden future growth.
Bears say
Biodesix is facing a cautious outlook because its Development Services pipeline is being pushed into 2027, limiting near-term revenue visibility despite contracted business rising only modestly to $8.7M from about $8.5M at 2Q-end. Management’s expectation of roughly $1M of Development Services revenue in 4Q and a 7–8% contribution of total revenue next year implies a slow recognition schedule, with study starts and sample shipments still gating conversion. Financial flexibility also looks tight, as it ended June 2026 with $30.0M in cash versus $50.0M in debt and posted ($1.6M) in operating cash flow during 2Q26, suggesting additional capital may be needed within the next 12 months.
This aggregate rating is based on analysts' research of Biodesix Inc and is not a guaranteed prediction by Public.com or investment advice.
Biodesix Inc (BDSX) Analyst Forecast & Price Prediction
Start investing in Biodesix Inc (BDSX)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Biodesix Inc (BDSX) Forecast
Biodesix Inc (BDSX) Analyst Forecast & Price Prediction
Start investing in Biodesix Inc (BDSX)
Order type
Buy in
Order amount
Est. shares
0 shares